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AbstRACt
background: Screening and treatment of pre‑cancerous lesions is important for prevention of cervical cancer. Currently, 
most available screening tests for cervical cancer are limited by low sensitivity, prohibitive costs, logistics and technical 
concerns. This study evaluates the role of multimodal hyperspectroscopy (MHS) as a cost‑effective, sensitive and user‑friendly 
point‑of‑care machine for early detection in women at risk of pre‑cancer lesions.
Materials and Methods: Multimodal hyperspectroscopy of the cervix using the LuViva® Advanced Cervical Scan was 
performed first in a 1‑minute procedure among 100 previously screened for cervical cancer using either visual inspection after 
application of acetic acid (VIA) or cytology within the last 120 days. This was then followed by obtaining human papilloma 
virus (HPV) samples and biopsies from women for histology.
Results: Of the 22 women with abnormal Pap tests of at least low‑grade squamous intraepithelial lesion, 3 had CIN2+, 
6 had CIN1, 4 were free of dysplasia at histopathology while 9 had cervicitis. All 3 of the CIN2+ recorded high likelihood of 
CIN2+ by MHS. However, HPV was negative for all 3 women. The machine classified 1 of 1 CIN1s and 7 of the 13 women 
without dysplasia or cervicitis as low or moderate risk for CIN2+ (40% specificity); of the 37 women who were VIA+, 
81% were classified as high risk, and 66% of 37 women with normal Pap tests and biopsy were either at moderate or low risk.
Conclusions: The findings from this pilot study show that MHS reduced the percentage of unnecessary colposcopy and 
biopsy by 37.5%. It was also able to differentiate between VIA+ and Pap negative women suggesting its potential of being 
a point‑of‑care primary and objective screening test.
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Introduction
Cervical cancer remains one of the leading causes of 
cancer-related mortality among women in developing 
countries with about 266, 000 of such mortalities per 
year.[1] Like most cancers, cervical cancer is easily treated 
if diagnosed early, and the uterine cervix is one of the few 
cancer-afflicted organs that can be accessed and visualized 
in a noninvasive manner. If detected in its pre-cancerous 
state, treatment can lead to almost a 100% survival rate at 
5 years.[2]
The Pap test, invented in the 1940s by Greek physician 
Georges Papanicalou, is the most common method for 
screening, especially in the developed countries of the world. 
Various meta-analyses have shown the detection rate or 
sensitivity of the Pap test to be highly variable, ranging 20–52% 
with a corresponding specificity of 90–95%.[3] Findings after a 
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Pap test can include atypical squamous cells of undetermined 
significance (ASC-US) and low-grade squamous intraepithelial 
lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL) 
or invasive cancer. Although these findings provoke 
millions of follow-up Pap tests, colposcopies and biopsies 
at a cost in excess of $6 billion annually, only about 5% of 
ASC-US and 10% of LSIL Paps actually reflect an underlying 
cervical intraepithelial lesion 3 (CIN3), an immediate cancer 
precursor.[4,5] In addition, for various reasons, many women 
with abnormal Pap tests are lost to follow-up before receiving 
a definitive diagnosis or appropriate intervention. Even with 
colposcopy, diagnosis is imperfect, with reported sensitivities 
ranging 53–85% for high-grade dysplasia[6-8] and reported 
specificities of 48% and 52% based on any dysplastic lesion 
detected. Therefore, a significant number of women have 
colposcopies and biopsies for benign conditions. Of the 
screening Pap tests conducted, approximately 8–9% result in 
ASC-US readings and approximately 5% are LSIL,[9] resulting in 
over 6 million potential ASC-US/LSIL triage tests. An additional 
2.24% are diagnosed as HSIL. Human papilloma virus (HPV) 
DNA testing is currently approved by the FDA for use in 
detecting the presence of the cancer-causing, high-risk HPV 
types. The American Society of Colposcopists and Cervical 
Pathologists (ASCCP) 2006 Consensus Guidelines indicate 
that ASC-US cytology findings can be followed either with 
HPV testing or repeat cytology. Women with LSIL cytology 
are referred to colposcopy if over the age of 20, but the new 
guidelines indicate that 12-month follow up is appropriate 
for women aged 20 and under. HPV testing is not indicated 
for use in young women due to its very high false positive 
rate and correspondingly low positive predictive value (10% in 
its intended use population according to the ALTS trial) or in 
women of any age with LSIL or HSIL as 84% of LSIL and nearly 
all of HSIL is HPV DNA positive. In addition, the Bethesda 
2001 (and 2008 revisions) cervical cytology guidelines[10] 
categorize ASCs as “undetermined significance (ASC-US)” or 
“cannot exclude HSIL (ASC-H),” the latter category can also 
refer directly to colposcopy.
The implication of these are the associated high expenses, 
both human and financial, to the patients, health care 
providers and to the society in general. Many women with 
benign cervical disease experience anxiety and confusion over 
ambiguous test results in addition to lost productivity and 
expenses to undergo invasive procedures. These procedures 
are not without risk, including possible morbidity due to 
over-referral. At the same time, excessive demand for repeat 
and/or invasive diagnostic procedures not only increases 
the cost of health care but also delays access to definitive 
diagnosis and treatment for some women who truly are at 
significant risk for developing cervical cancer. This problem 
has been exacerbated by the recently documented increase 
in false positive results produced by the increased use of thin 
layer cytology and HPV testing.[11]
There remains, therefore, a significant need for a point-of-care 
test to improve the screening and diagnosis as well as 
management of cervical disease, especially for improving 
sensitivity and lowering the false positive rate. Such 
point-of-care tests include devices based on the principle 
of fluorescence and reflectance spectroscopy. Fluorescence 
and reflectance spectroscopy have been shown to be 
valuable in cancer diagnosis by several investigators. An early 
review has outlined the various spectroscopic methods and 
challenges.[12] However, much of the work done in this area 
has been on excised tissue. Several biophysical changes occur 
rapidly within tissue following excision. For example, changes 
in blood oxygenation and perfusion in the tissue vasculature 
cause changes in the reflectance readings and the change 
in the redox state of NADH, a key tissue fluorophore that 
affects fluorescence measurements made using 340–350 nm 
excitation which, in our view, may have limited utility as 
criteria for in‑vivo diagnostics.
Several groups are investigating the potential of spectroscopic 
techniques to provide a quantitative measure of neoplasia 
without tissue removal. The main advantage of such 
spectroscopic techniques relies on their being able to detect 
and quantitatively assess changes in the cellular milieu and 
tissue architecture associated with the progression of disease. 
Several in‑vivo studies appear in the literature showing 
the performance of either fluorescence or reflectance 
spectroscopy in discriminating between normal tissue and 
different epithelial cancer grades. These include cervical,[13-16] 
colon,[17-20] gastrointestinal tract,[21] skin[22] and lung[23] cancers. 
These studies use point measurements of areas that are either 
suspect or normal based on heuristic determinations. For 
cervical cancer and its precursors, sensitivities in the range 
of 80–90% and specificities in the range of 70–80% have been 
reported for discriminating between LSIL and HSIL. Only a 
few investigators have used multiple spectroscopic modes 
to improve their diagnoses, and in these cases, improvement 
over individual modes has been documented.[24] By using 
multimodal spectroscopy in an imaging system, a unique, 
cost-effective approach that has the potential to reduce 
morbidity from over treatment due to unnecessary referrals 
and significantly improve patient care while simultaneously 
reducing the enormous costs currently associated with 
cervical disease management was developed. One of such 
devices is LuViva® (Guided Therapeutics, Norcross, GA 
USA), a multimodal hyperspectoscopic (MHS) device.[25] The 
device non-invasively collects and analyses fluorescence and 
reflectance spectra from the cervix without contrast agents 
such as acetic acid. Light from the arc lamp is band passed, 
Awolude, et al.: Multimodal hyperspectrosopy in cervical cancer prevention
136 Tropical Journal of Obstetrics and Gynaecology / Volume 34 / Issue 2 / May‑August 2017
filtered to limit exposure of the cervix to three distinct 
regions centered at 340 nm, 400 nm and 460 nm, which 
excites fluorophores associated with neoplastic processes. 
The resultant fluorescent spectral output of the cervical 
tissue is imaged onto a charge coupled device (CCD) camera 
and stored for processing and analysis. In addition to the 
fluorescence and reflectance spectroscopy channel, the 
LuViva also contains a separate colposcopy quality imaging 
channel. The purpose of this imaging channel is two-fold: 
(1) to allow real-time imaging of the cervix for centration 
guidance while the cervical guide is being placed inside the 
vagina and (2) to allow images to be taken for documenting 
the placement of the device and appropriate centering of 
the cervix within the 1-inch diameter measurement area.[26]
We, therefore, set to evaluate this MHS (LuViva®) for the 
early detection of cervical cancer in a population of women 
at risk of cervical cancer.
Patients and Methods
Study population
The participants in this study were 100 women previously 
screened for cervical cancer using either VIA or conventional 
cytology, irrespective of the result, within the last 120 days 
prior to the day of enrollment. To be considered for 
enrollment in the study, a participant had to be 21 years 
old or above, able to give informed consent, had a negative 
pregnancy test or with documentation of acceptable birth 
control and willing to undergo LuViva®, HPV testing, 
colposcopy and biopsy of the cervix on the day of the study 
following previous positive VIA test, normal cytology test, 
LSIL or HSIL from cytology screening. A potential participant 
was not considered for enrollment in the study when she had 
any pregnancy, menstruating, previous macroscopic cervical 
disease or prior hysterectomy. Moreover, conditions relating 
to the cervix that would render the test difficult to perform, 
including but not limited to excessive blood or mucus that 
cannot be removed, congenitally or acquired abnormal 
cervix or inability to tolerate speculum or LuViva® single 
use cervical guide, made a woman ineligible for enrollment.
Study procedure
Each participant had, after consenting to the study, placement 
of the LuViva® system. A video image from the device was used 
to guide placement of the hollow cervical guide for centering 
of the cervix in the visual field, capture locations of lesions 
for comparison with the spectroscopic image and as a quality 
check after spectroscopic measurements for detecting whether 
excessive movement of the cervix occurred or if there was 
excessive mucous or blood. Hyperspectroscopy of the cervix 
using the LuViva® Advanced Cervical Scan was performed in 
a 1-minute procedure. After the LuViva® test, a sample for 
Hybrid Capture 2 HPV testing, using a cytobrush was collected 
for all patients followed by colposcopy and biopsy from the 
ectocervix after application of 5% acetic acid from the observed 
abnormal area and from the quadrants if no obvious abnormality 
was observed. If a lesion was not seen with acetic acid, Lugol’s 
solution was applied. Thus, the gold standard will be negative 
VIA and negative HPV for women diagnosed as normal and most 
severe histopathology result for women with disease. A key 
component of effective screening studies designed to evaluate 
new detection modalities is verification of the gold standard 
comparison by which estimates of sensitivity and specificity are 
generated. Prior to beginning this pivotal trial, the site study 
team were trained on 5 patients. Data from these training cases 
were not included in the clinical trial data set.
Results
The participants’ baseline characteristics analysis showed that 
the mean age was 44.2 (SD = ±8.2) years. Most women (84%) 
were multiparous with a modal parity of 3. The mean age at first 
sexual exposure was 17.1 (SD = ±3.5) years, and the mean age 
at first delivery was 26.4 (SD = ±2.6) years (Table not shown).
In this pilot study, 26 of the 100 participants were referred 
to colposcopy based on an abnormal Pap result, 37 based 
on positive VIA test and 37 with normal Pap smear results 
to serve as control.
Table 1 shows the cytology and VIA results as a function of 
histopathology. Of the 37 patients with negative results from 
cytology, histopathology could identify 5 (13.5%) as normal, 
4 (11.4%) as CIN I; 2 (5.4%) as CIN 2 and 2 as CIN 3 (1 with and 
without cervicitis each). There were 24 (64.9%) cases with 
various degree of cervicitis without dysplastic changes. 
Histopathology confirmed 1 of the ASC-US as CIN 3 and 
the other one as normal while the 2 atypical glandular cells 
(AGC) were confirmed non-dysplastic (one each with and 
without cervicitis) by histopathology. Four of the 16 LSIL were 
confirmed normal, 6 with cervicitis, 5 as CIN 1 (3 without 
and 2 with cervicitis, respectively), one case of CIN 2 with 
cervicitis and no case of CIN 3 with histopathology while 3 of 
the HSIL were confirmed with cervicitis with 1 each confirmed 
as CIN 2 and CIN3, respectively, with histopathology. For the 
37 participants referred based on positive VIA, 11 (29.7%) 
were confirmed normal by histopathology, 17 (45.9%) with 
cervicitis, 5 as CIN 1 (one without and 4 with cervicitis, 
respectively), 4 (10%. 8) as CIN2 (one without and 3 with 
cervicitis, respectively) and none as CIN3. From this study, 
the overall sensitivity of cytology in identifying dysplastic 
changes of the cervix was 60% and specificity of 64.4% while 
for VIA it was 68.4% and 69.1%, respectively.
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An important finding from this study is the high rate of 
cervicitis in the patients at 62% (62/100). While the cervicitis, 
in various degree of severity, was the only histopathological 
finding in 51 of the 62 cases and with no dysplastic changes, 
it was a co-existing finding in 6 of the 15 cases of CIN 1, 4 of 
the 8 cases of CIN 2 and 1 of the 4 cases of CIN 3.
In all 14 histopathology confirmed cases of CIN1 of which 
5 (35.7%) were recorded RED (high likelihood of CIN2+) by 
MHS, 8 cases of CIN 2 of which 7 (87.5%) were recorded RED 
and 4 cases of CIN3 all (100%) of which were recorded as RED. 
Using CIN2+, the sensitivity of MHS at RED threshold was 
91.7% (11/12). Of the 51 cases diagnosed with cervicitis only, 
histopathologically 10 (19.6%) were recorded as GREEN (low 
likelihood of CIN2+) and 7 (13.7%) were recorded as YELLOW 
by MHS whereas the remaining thirty-four (66.7%) were 
recorded as RED by MHS.
Overall, 11.2% (11/98) of all women in the study were positive 
for high-risk HPV [Table 2]. This included 5 of the 69 with 
normal histopathology results, 2 of 17 CIN1, 1 of 6 CIN2 and 
3 of the 6 with CIN3.
In all the sensitivity of MHS in identifying any dysplastic lesion 
of the cervix was 92.3% whereas the specificity was 37.5%.
Discussion
Characteristics of the participants
This pilot study evaluated the ability of LuViva (R), an MHS 
device, to correctly identify women at risk for cervical cancer 
in mixed population of previously screened women. A study 
using the same device in our environment was among women 
without prior cervical cancer screening history.[27]
Cytology and VIA+ results as a function of histopathology
Sixty-five of the 100 women in the study were referred to 
colposcopy based on either an abnormal Pap result or a 
positive VIA. Visual inspection with application of acetic 
acid could identify 7 CIN1, 5 CIN2 and only 1 CIN3, which 
is the goal of screening. Referral of patients with Pap 
smear results at the LSIL threshold identified 5 of 10 CIN1 
as positive, missed 1 CIN2 and identified 3 of 5 CIN3 as 
positive (sensitivity of 60%). At histopathology, 3% of the VIA 
positive cases and 12% of the LSIL cases from cytology were 
diagnosed as CIN 3.
Cervical inflammation has been hypothesised to be capable 
of influencing the carcinogenic process of the cervix driven 
by HPV.[28] The cervicitis, especially the infective types, can be 
risk factors for the persistence of HPV[29] and the chronically 
induced dysplatic lesions. These and the high rate of cervicitis 
of 62% in this study might suggest the need for further studies 
to ascertain the role of genital microbial co-infection with 
HPV in the aetiopathogenesis of cervical pre-cancer and 
cancer lesions.
Positive HPV results were lower among these patients than 
expected based on the population of referred women who 
were previously screened. In all, only 11.2% of 98 women 
with HPV results in the study were positive for high-risk 
HPV (hrHPV). This included 5 of the 69 women with normal 
histopathology and available HPV results 2 of the 17 CIN 
1 (11.8), only 1 of 6 with CIN2 (16.7%) and 3 of 6 with 
CIN3 (50.0%). The reasons for this are not completely clear 
but could include pre-, intra-, or post-analytical errors 
and/or degradation due to environmental conditions. Another 
possible explanation might be the average age of women 
in the study which was 45 years. Studies have shown that 
HPV infection rates can be much lower in women above the 
age of 40 and that the sensitivity of HPV is also lower in this 
Table 1: Cytology and VIA+results as a function of histopathology
Cytology Histopathology
Normal Cervicitis CIN I CIN I+ cervicitis CIN II CIN II+ cervicitis CIN III CIN III+ cervicitis Total
Negative 5 24 4 0 2 0 1 1 37
ASCUS 1 0 0 0 0 0 1 0 2
AGC 1 1 0 0 0 0 0 0 2
LSIL 4 6 3 2 0 1 0 0 16
ASC-H 0 0 0 0 0 0 0 0 0
HSIL 0 3 1 0 1 0 1 0 6
VIA+ 11 17 1 4 1 3 0 0 37
Total 22 51 9 6 4 4 3 1 100
22 51 15 8 4
Table 2: HPV results as a function of histopathology
HPV results Histology
Normal CIN 1 CIN 2 CIN 3
HPV+ 5 2 1 3
HPV- 64 15 5 3
HPV (no result) 2 0 0 0
Total 71 17 6 6
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age group.[30] In support of this, we found that HPV false 
negatives occurred more in older Nigerian women (median 
age = 51.5 years) compared with women having true positive 
HPV results (median age = 43.0 years), although sample 
sizes are small.
Multimodal hyperspectroscopy triage performance
Of the 100 women enrolled in the study, 20 qualified as 
Luviva® screening for possible triage based on referral 
Pap results of ASC-US/AGUS (n = 4) or LSIL (n = 16). An 
additional 6 patients with HSIL Pap smear were tested, 
however, HSIL is contra-indicated for Luviva® due to the high 
likelihood of significant cervical disease. Of the 24 women 
with abnormal Pap smear of at least LSIL, 3 were found to 
have CIN2+ at histology. All these 3 recorded RED (high 
likelihood of CIN2+) by Luviva® giving 100% sensitivity. 
It is of interest that HPV was negative for all 3 of these 
patients. Review of the remaining 21 women without 
CIN2+ showed that 5 were found to have CIN1, of which 
LuViva® recorded four as RED (high likelihood of CIN2+) and 
one as YELLOW (moderate likelihood of CIN2+). Fifteen of 
the referred patients were found to have cervicitis (n = 9) 
or normal histology (n = 6), 5 of whom were recorded as 
GREEN (low likelihood of CIN2+) and 2 were recorded as 
YELLOW (moderate likelihood of CIN2+) by Luviva®. The 
remaining 8 were recorded as RED (high likelihood of CIN2+) 
by Luviva®. Therefore, the sensitivity and specificity of the 
triage patients were as follows. At the Green/Yellow threshold, 
the Luviva® cervical scan sensitivity was 100% for cervical 
lesions with likelihood of CIN2+ while the specificity was 
33%. The sensitivity remained 100% at Yellow/Red threshold 
with slight improvement of the specificity to 40% [Table 3].
Screening performance of Luviva® cervical scan device
Because the prevalence of CIN2 and especially CIN3 was very 
small in the population of women with normal Pap results we 
compared the Luviva® results for women screened positive 
by visual inspection with acetic acid (VIA+; n = 37) with 
those with Negative Pap results (n = 37). Using the Luviva® 
algorithm developed for triage of HPV+ (but Pap negative) 
referred patients, 23 of the 35 women (66%) with negative Pap 
results produced a LuViva result in the GREEN (low likelihood 
of CIN2+) or YELLOW (moderate likelihood of CIN2+) zone, 
whereas only 7 of the 36 VIA+ women did (19%). Thus, 
LuViva could differentiate VIA positive women from Pap 
negative women at a sensitivity of 81% and a specificity of 
66%. Additional work with larger populations is needed to 
re-calibrate LuViva®’s algorithms to identify CIN3+ cases 
within screened populations.
Strength and limitations
The main strength of our study is its inclusion of both 
screened negative women and women referred as VIA and 
cytology positive, thus giving the examiners a wide range of 
participants with normal to pathological cervical status and 
a reduction of the risk of selection bias. Other strengths are 
that all the biopsies were analysed in a single-site laboratory 
and the included women were all examined in a single centre. 
Moreover, screening with the hyperspectroscopy device was 
performed by the same person, thus reducing the problem 
of intra-observer variations. The main weakness of our study 
is the small sample size making the result less generalizable. 
However, as a pilot, especially in a developing country, it is 
a template for a larger study.
Conclusion
This study showed that MHS when used in clinical setting 
has 92.3% sensitivity of identifying pre-cancer lesions of 
the cervix. It also reduced the percentage of unnecessary 
colposcopy and biopsy by 37.5% without any false negative 
result. These findings were consistent with other studies 
conducted in North America.[25,26] It has the added advantage 
to differentiate between VIA+ and Pap negative women. The 
implication of all these is that the machine has the potential 
of being a point-of-care primary and objective screening test 
for pre-cancer lesions of the cervix.
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